EPO Fees 2016

February 2016

Fees for European patents are adjusted by the EPO every two years; this year will see the first increase since 2014.

The EPO has published the fees that will apply from 1 April 2016. Most fees will see a small increase of around 1-2%, but many are not increasing at all. See CA/D 12/15 for the information in full.

The new fees shall be applicable for payments made on or after 1 April 2016, rather than on the due date of the fee. Click here to view the schedule.

For more information on the revised fees, please contact your usual HGF attorney.

This update was prepared by Mark Lunt, Partner in our Sheffield office.

If you would like further advice on this or any other matter please contact Mark or your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Updates — In this section

Updates
News
Events
Blog
Retail Scanner Newsletter

All latest updates

Oxford Bacteriophage Conference 2017
September 2017
HGF Partner Craig Thomson will be Co-presenting "Creating Impact: The challenges and opportunities of commercialisation in the field of bacteriophage research" alongside Professor Martha RJ Clokie.
Read More
IP in Retail Conference 2017
September 2017
IP in Retail 2017 - HGF's fifth annual conference will be held in September in Leeds and London. The conference addresses topical IP issues for retailers.
Read More
CpG Oligonucleotide Therapeutics - A History Lesson for CRISPR?
July 2017
When we look at the emerging and likely future battles being fought to establish dominance in the emerging field of CRISPR technologies, it may be too easy to conclude that one has no frame of reference to help understand what the conclusion will likely be. However, as Harry S Truman said; “There is nothing new in the world except the history you do not know”. There have, of course, been many emerging technologies that have been subject to an IP land-grab. One such instance that we will look at in this article relates to CpG oligonucleotides.
Read More
UPC Agreement Provisional Application Phase and What’s Next
July 2017
The UK has deposited the document required to apply the Protocol to the Agreement on a Unified Patent Court on provisional application (PPA) with the depository for the UPC Agreement.
Read More
UK Patent Equivalents, Exclusions and Estoppel – where are we now?
July 2017
A 5 year battle between Eli Lilly (Lilly) and Actavis centred on Lilly’s patent for the use of pemetrexed disodium for cancer therapy, has culminated in a decision from the UK Supreme Court, allowing Lilly’s appeal and deciding that Actavis' Products directly infringe Eli Lilly's patent in the UK, France, Italy and Spain. The Court also dismissed Actavis' cross-appeal on the basis that if its products did not directly infringe, they would indirectly infringe to the extent held by the Court of Appeal. Full judgment here.
Read More

EPO Fees 2016

February 2016

This update was prepared by Mark Lunt, Partner in our Sheffield office.

If you would like further advice on this or any other matter please contact Mark or your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Updates — In this section

All latest updates

Oxford Bacteriophage Conference 2017

IP in Retail Conference 2017

CpG Oligonucleotide Therapeutics - A History Lesson for CRISPR?

UPC Agreement Provisional Application Phase and What’s Next

UK Patent Equivalents, Exclusions and Estoppel – where are we now?